The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.c

Pleural thickening - Fibrothorax

Publications

Belmonte Y, de Fàbregues O, Marti M, Domingo C

Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.

The open respiratory medicine journal. 2009;3:90-3

Andersohn F, Garbe E

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.

Movement disorders : official journal of the Movement Disorder Society. 2009;24(1):129-33

Müller T, Fritze J

Fibrosis associated with dopamine agonist therapy in Parkinson's disease.

Clinical neuropharmacology. 2003;26(3):109-11